| Autor: |
Bratt, Göran, Eriksson, Lars E., Sandström, Eric, Gilljam, Gustav, Hinkula, Jorma, Albert, Jan, Redfield, Robert, Wahren, Britta |
| Předmět: |
|
| Zdroj: |
International Journal of STD & AIDS; Aug1999, Vol. 10 Issue 8, p514-521, 8p, 4 Charts, 1 Graph |
| Abstrakt: |
Forty asymptomatic HIV-infected individuals with CD4+ lymphocyte levels above 400 106/l were immunized over 5 years with recombinant envelope glycoprotein gp160 (rgp160). After 5 years there was a trend towards more nonprogressors in the immunized group as compared to the matched controls. Since immunizations could activate HIV, the first 6 immunizations were followed by 2 weeks of zidovudine or placebo, double-blind. The viral load did not change during the first 6 months and was not different from that of the matched controls after 5 years. The best effect on CD4+ lymphocyte development was seen in individuals with a high viral load randomized to rgp160+zidovudine and in individuals with a low viral load randomized to rgp160+placebo. We conclude that rgp160 is safe and results in temporarily improved CD4+ development. Concomitant antiviral treatment might be of benefit, especially in patients with a more advanced disease and can today be given with more effective combinations. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
